Background: Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treatment effect, but there may be strong justification for borrowing information from a larger patient group within the same trial, while allowing for differences between populations. Our aim was to develop methods for eliciting expert opinions about differences in treatment effect between patient populations, and to incorporate these opinions into a Bayesian analysis. Methods: We used an interaction parameter to model the relationship between underlying treatment effects in two subgroups. Elicitation ...
In the conduction of trials, a common situation is related to potential difficulties in recruiting t...
AbstractObjectivesFindings from nonrandomized studies on safety or efficacy of treatment in patient ...
In drug development, it sometimes occurs that a new drug does not demonstrate effectiveness for the ...
BACKGROUND: Clinical trial investigators may need to evaluate treatment effects in a specific subgro...
Background Clinical trial investigators may need to evaluate treatment effects in a specific subgrou...
textIn randomized clinical trials, medical researchers are interested to determine the effectiveness...
Background: Subgroup analyses are common in randomised controlled trials (RCTs). There are many eas...
Large randomized controlled clinical trials are the gold standard to evaluate and compare the effect...
BACKGROUND: In order to use the results of a randomised trial, it is necessary to understand whether...
Objective When developing new medicines for children, the potential to extrapolate from adult data t...
University of Minnesota Ph.D. dissertation. May 2017. Major: Biostatistics. Advisor: Bradley Carlin....
When randomized trial results are available for several different groups of patients, neither applyi...
Important objectives in the development of stratified medicines include the identification and confi...
\ua9 2022 The Authors. Journal of the Royal Statistical Society: Series C (Applied Statistics) publi...
Background: When the treatment effect on the outcome of interest is influenced by a baseline/demogra...
In the conduction of trials, a common situation is related to potential difficulties in recruiting t...
AbstractObjectivesFindings from nonrandomized studies on safety or efficacy of treatment in patient ...
In drug development, it sometimes occurs that a new drug does not demonstrate effectiveness for the ...
BACKGROUND: Clinical trial investigators may need to evaluate treatment effects in a specific subgro...
Background Clinical trial investigators may need to evaluate treatment effects in a specific subgrou...
textIn randomized clinical trials, medical researchers are interested to determine the effectiveness...
Background: Subgroup analyses are common in randomised controlled trials (RCTs). There are many eas...
Large randomized controlled clinical trials are the gold standard to evaluate and compare the effect...
BACKGROUND: In order to use the results of a randomised trial, it is necessary to understand whether...
Objective When developing new medicines for children, the potential to extrapolate from adult data t...
University of Minnesota Ph.D. dissertation. May 2017. Major: Biostatistics. Advisor: Bradley Carlin....
When randomized trial results are available for several different groups of patients, neither applyi...
Important objectives in the development of stratified medicines include the identification and confi...
\ua9 2022 The Authors. Journal of the Royal Statistical Society: Series C (Applied Statistics) publi...
Background: When the treatment effect on the outcome of interest is influenced by a baseline/demogra...
In the conduction of trials, a common situation is related to potential difficulties in recruiting t...
AbstractObjectivesFindings from nonrandomized studies on safety or efficacy of treatment in patient ...
In drug development, it sometimes occurs that a new drug does not demonstrate effectiveness for the ...